Avecho Biotechnology Limited · ASX:AVE
Avecho Biotechnology — Investor Presentation (March 2025)
16 slides from Avecho Biotechnology's investor presentation, Mar 4, 2025
Slide 1: Avecho Investor Webinar and Presentation
ASX Announcement 4 March 2025 Avecho Investor Webinar and Presentation Melbourne, Australia, 4 March 2025: Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”) invites Shareholders to attend its investor webinar to be held today, Tuesday 4 March 2025, at 11.00am (AEDT), following the
Slide 2: About Insomnia and Phase III Trial Program
About Insomnia Insomnia is a sleep disorder defined as dissatisfaction with sleep quantity or quality associated with difficulty initiating sleep, difficulty maintaining sleep and the inability to return to sleep on awakening. It can manifest as a primary indication or be symptom of other disorders,
Slide 3: Forward-looking statements
No representation, warranty or assurance (express or implied) is given or made by Avecho that the forward-looking statements contained in this announcement are accurate, complete, reliable or adequate or that they will be achieved or prove to be correct. Except for any statutory liability which cann
Slide 4: Licensing Webinar March 2025
For personal use only Licensing Webinar March 2025 www.avecho.com.au | ASX:AVE
Slide 5: Safe Harbour Statement
This presentation, and any differences may be material representations made before, during (whether positive or negative). or after the presentation, may The risks that may cause Avecho‘s Safe Harbour include forward-looking statements actual results, performance or For personal use only that are in
Slide 6: Summary
Summary For personal use only Phase 3 Opportunity Drug Product Commercial Validation › TPM-enhanced cannabidiol (CBD) capsule for insomnia › Commercial licensing deal with Sandoz for Australia › In a pivotal Phase III clinical trial › Attractive terms: substantial revenue upon commercialization Inso
Slide 7: Ideal partner for Avecho's CBD insomnia capsule
Large pharmaceutical company Financial stability Ideal partner For personal use only R&D Capabilities for Avecho’s Experience in the clinical development of new medications CBD insomnia Regulatory expertise Strong understanding of Australian TGA regulatory requirements capsule Significant interest i
Slide 8: About Sandoz
Swiss-based multinational Focus on driving access to make a real For personal use only pharmaceutical company spun difference for patients worldwide1 out of Novartis (Market Cap ~$US 20Bn) Purpose Vision Global presence with Pioneering access To be the world’s leading and most valued a portfolio of
Slide 9: Strong Australian presence
Australia‘s 2nd largest generics and biosimilars company with a dedicated team focussed on driving OTC medicines For personal use only Nationwide presence and strong partnerships with major pharmacy banner groups Robust distribution network already in place, with the capability to supply every pharm
Slide 10: Partnership Key Terms
Partnership For personal use only Key Terms Sandoz acquires exclusive rights to Avecho’s pharmaceutical Avecho responsible for the completion of the Phase cannabidiol capsule for insomnia in Australia. III trial and supporting development activities Avecho to receive upfront, milestone and royalty p
Slide 11: Forecast market size
Forecast market size For personal use only Insomnia is broadly defined as difficulty initiating or maintaining sleep It affects 10-30% of the population, with 10- 15% of the population classified as chronic1,2 Globally Up to 237M people are affected4 9.5M 3.6M people in Australia people in Australia
Slide 12: Commercial Growth Phase
Europe 20x For personal use only Canada 1.5x Commercial USA 30x China 10x Growth Phase MENA 2x Japan 5x › Commercial validation from multinational pharmaceutical company LATAM 4x › New phase of commercial growth following many Partnered years of hard work advancing the CBD capsule › Australia the fi
Slide 13: Phase III Interim Analysis
Assessments › Daily sleep diary to record nightly sleep. Phase III Interim Analysis include › Sleep questionnaire every two weeks. For personal use only Next Major › Secondary endpoints related to anxiety Milestone Interim › As of December 2024, 70 patients have Analysis received study medication 8-
Slide 14: Increasing shareholder value: Dimerix Case Study
Increasing shareholder value For personal use only Dimerix Case Study 5 Dimerix (ASX:DXB) are in a Phase III clinical trial for Focal Segmental Glomeruloscelosis (FSGS) Orphan indication (<200,000 patients in the US) 4 1. Phase III trial underway: ~$26M market cap 3 2. First licensing deal (ANZ, EU,
Slide 15: The year in front of us
The year in front of us For personal use only Complete Partner Partner TGA Trial Complete Sign commercial Complete Phase III Partner discussions Commence partner for CBD trial to interim analysis for CBD product in build of TGA insomnia product in › Discuss results with TGA. further territories subm
Slide 16: Questions Welcome
Questions Welcome For personal use only Dr Paul Gavin Melbourne Office Chief Executive Officer Unit A8, 2A Westall Road T. +61 3 9002 5000 Hallmarc Business Park E. pgavin@avecho.com.au Clayton VIC 3168 Australia T: +61 3 9002 5000 E: info@avecho.com.au
Avecho Biotechnology — Investor Presentation (March 2025) on 6ix